Trastuzumab duocarmazine not checked
Byondis B.V. · SYD985
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.”In the company’s words, NCT02277717 on ClinicalTrials.gov
- Main trialPhase 3
- “The purpose of this study is to demonstrate that SYD985 \[(vic-)trastuzumab duocarmazine\] is superior to physician's choice in prolonging progression free survival.”In the company’s words, NCT03262935 on ClinicalTrials.gov
- Other names
- SYD985 · Trastuzumab vc-seco-DUBA
Other drugs for Metastatic Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 31 Mar 2021 | SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | |
| Phase 2Completed | 26 Jan 2023 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | |
| Phase 1Completed | Jan 2019 | First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients | |
| Phase 1Completed | 24 Apr 2023 | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026